Monograph

J07BC01 - Hepatitis B, Purified Antigen

Propably not porphyrinogenic

Rationale

Based on the pharmacokinetics of the hepatitis B, purified antigen vaccine, there are no conceivable porphyrinogenic effects.

Chemical description

Hepatitis B surface antigen

Therapeutic characteristics

The vaccine is indicated for the active immunization of adults, children and infants against hepatitis B. It is administered by intramuscular injections according to a three or four dose schedule.

Metabolism and pharmacokinetics

The hepatitis vaccine is not metabolized by the cytochrome P450 system.

IPNet drug reports

Uneventful use reported in 1 patient with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes J07B / J07BC or go back.

References

#	Citation details	PMID
*	Government bodies
1.	Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
*	Summary of Product Characteristics
2.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). HBVAXPRO. (Last edition: March 2014).

Citation details

PMID

Government bodies

Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). HBVAXPRO. (Last edition: March 2014).

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames